Genfit files for NASDAQ listing

France’s Genfit S.A. (Euronext:GNFT) proposed a NASDAQ offering that would give the company a dual listing. The company, whose lead molecule elafibranor is in Phase III testing to treat non-alcoholic steatohepatitis (NASH), proposed to raise a total of up to $100 million through the sale of ADSs to public investors and via a concurrent ex-U.S. private placement, primarily with European investors.